Registration is now closed.
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
Postoperative TSH Levels Did Not Affect Recurrence After Thyroid Lobectomy in Patients With Papillary Thyroid Cancer
- Presentation Speakers / Moderators
Background/Purpose: Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy.
Methods: Patients (n = 1528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean, median, and dominant TSH values during the entire follow-up period of 5 years, patients were divided into four groups (<0.5 mIU/L, 0.5–1.9 mIU/L, 2.0–4.4 mIU/L, and ?4.5 mIU/L). Recurrence-free survival was compared among the groups.
Results: During the 5.6 years of follow-up, 21 (1.4%) patients experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5–1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean, median, and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.
Discussion & Conclusion: Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.
Two Approaches to Level 5 Neck Dissection
- Jeff Blumberg